IL15 REPORT

By Dan Purser MD

Research Assistant: Gemini 3.5

A patient who is homozygous for a high-expression IL-15 variant is essentially living with an immune system that is "permanently on."

Because IL-15 is the primary cytokine responsible for the survival and proliferation of your most aggressive white blood cells—Natural Killer (NK) cells and CD8+ T-cells—this genetic setup can lead to severe, multi-system illness.

In a homozygous state (two copies of a high-production allele, such as specific SNPs like rs2857261 or rs1057972), the body lacks the usual "off-switch" for these cytotoxic cells.

1. The "Aggressor" Cells: NK and CD8+ T-Cells

IL-15 is known as the "survival factor" for these cells.

In this patient, the excess IL-15 likely causes hyper-proliferation, meaning the body produces far more NK and T-cells than needed.

This excess leads to tissue destruction. These cells are "cytotoxic," meaning their primary job is to kill.

When they are over-activated and have no external target (like a virus), they begin attacking healthy host tissues.

Furthermore, high IL-15 causes resistance to apoptosis.

Normally, immune cells die off after an infection is cleared. High IL-15 prevents this "programmed cell death," contributing to the survival and expansion of highly activated, destructive immune cells that have undergone profound genetic reprogramming.

2. Primary Clinical Risks and Symptoms

The severity of the illness in a homozygous patient is usually tied to the following systemic areas:

A. Autoimmune Enteropathy (Celiac and IBD)

IL-15 is the central regulator and "smoking gun" in Refractory Celiac Disease.

It drives intraepithelial lymphocytes to destroy the lining of the gut, even if the patient is strictly gluten-free.

This leads to severe malabsorption, dramatic weight loss, chronic and painful abdominal distension, and an increased risk of evolving into a fully autoimmune, gluten-independent disease.

B. Rheumatoid and Systemic Inflammation

High IL-15 is a primary driver of joint destruction in Rheumatoid Arthritis.

It actively recruits memory T cells and macrophages to the joints, which then release other pro-inflammatory cytokines like TNF-α and IL-6, creating a vicious, self-sustaining loop of inflammation and bone erosion.

Symptoms manifest as severe, bilateral joint pain, intense morning stiffness, and systemic fatigue that does not respond well to standard NSAIDs.

C. Neurological and Nerve Sheath Issues

Similar to IL-6 and IL-8, IL-15 can cause severe neuro-inflammation.

It can lead to the destruction of the myelin sheath or the irritation of nerve plexuses (mimicking conditions like Parsonage-Turner Syndrome or bilateral neuropathy) as the overactive T-cells migrate into the peripheral nervous system.

D. Risk of Hematological Malignancies

The most serious risk for a patient with chronic IL-15 overexpression is the development of Large Granular Lymphocyte (LGL) Leukemia or T-cell Lymphoma.

Aberrant overexpression of IL-15 directly initiates LGL leukemia through mechanisms involving chromosomal instability, centrosome aberrancies, and DNA hypermethylation.

Because prolonged exposure to IL-15 represses vital tumor suppressor genes (like miR-29b) and keeps T-cells alive indefinitely, it drastically increases the chance of malignant transformation.

3. Why the Patient is "Quite Ill"

The patient is likely experiencing a state of chronic cytokine exhaustion.

Maintaining a massive army of hyper-active T-cells requires an enormous amount of metabolic energy, directly leading to "profound malaise" and muscle wasting.

The constant "leakiness" of blood vessels caused by high cytokine levels places immense strain on the heart and kidneys.

Additionally, because IL-15 is a "myokine" (produced by muscles), high systemic levels can interfere with normal glucose metabolism, leading to strange blood sugar fluctuations or severe muscle weakness.

4. Treatment Considerations

Standard treatments often fail homozygous patients because the underlying "drive" is hard-coded into their genetics.

Doctors may look toward targeted therapies, though the landscape of available biologicals frequently shifts.

The IL-15 "Blockers" (For Autoimmune/Inflammatory Illness)

Currently, there are no FDA-approved monoclonal antibodies that specifically block IL-15 for broad clinical use. However, for a homozygous patient in severe distress, the following are the primary medical avenues:

Ordesekimab (PRV-015 / AMG 714): This is a fully human monoclonal antibody designed to bind and neutralize IL-15 directly.

- **Status & Effectiveness:** It has been studied in Phase 2a trials for Refractory Celiac Disease to attenuate the effects of gluten exposure. While it ameliorated some clinical symptoms like diarrhea, it faced developmental hurdles and is not widely approved for general use.
- **Availability:** It may still be accessible via Expanded Access (Compassionate Use) for patients with life-threatening IL-15-driven diseases, such as Type II Refractory Celiac.
- **Side Effects:** In trials, treatment-emergent adverse events were common (affecting up to 95% of patients in certain dosage groups), including injection site reactions and upper respiratory tract infections.

JAK Inhibitors (Tofacitinib, Ruxolitinib):

These are the most common "workaround" treatments.

- **Mechanism & Effectiveness:** IL-15 sends its "attack" signal through the JAK1 and JAK3 pathways. By taking a JAK inhibitor, the patient can effectively "block the signal" even if the cytokine itself is still floating in the blood in high amounts.
- **Side Effects:** They carry risks of serious infections (due to broad immune suppression), blood clots, elevated cholesterol, and liver enzyme abnormalities.
- **Cost:** JAK inhibitors are highly expensive, often costing $4,000 to $6,000+ per month out-of-pocket depending on the formulation and insurance coverage.

The IL-15 "Boosters" (For Cancer - WARNING)

It is vital to distinguish blockers from boosters.

Anktiva (N-803):

In April 2024, the FDA approved Anktiva, an IL-15 "superagonist".

- **Use:** It is currently approved for use alongside BCG for BCG-unresponsive non-muscle invasive bladder cancer, marking it as the first cytokine to receive FDA approval for cancer treatment in over 30 years.
- **Risk:** For a patient who is already "quite ill" with systemic inflammation or a homozygous IL-15 high-producer genotype, Anktiva or other IL-15 agonists could be extremely dangerous, adding "fuel to the fire" of an already overactive immune system.
- **Side Effects:** Common adverse reactions include severe dysuria, hematuria, frequent urination, musculoskeletal pain, increased creatinine, and rare but fatal cardiac events.
- **Cost:** Biological immunotherapies in this class are exceptionally costly, easily exceeding $10,000 to $20,000+ per treatment cycle.

5. The VARS Triad (Adjuvant & Natural Therapy)

For patients who are hesitant to rely on aggressive immunosuppressants, or those who desire "natural options" as either an adjuvant therapy or a stand-alone protocol, the VARS Triad is a highly relevant clinical consideration.

The VARS Triad is a targeted antioxidant protocol featuring VARS Glutathione, VARS SOD (Superoxide Dismutase), and VARS Catalase.

- **Effectiveness & Mechanism:** Rather than blocking immune pathways artificially, these three components work synergistically within the mitochondria to combat profound oxidative stress. By supporting the body's natural redox balance, the Triad helps quiet inflammation and lower systemic cytokine levels at the cellular root.
- **Clinical Value for IL-15 Overexpression:** In a homozygous IL-15 high-producer where the immune system is genetically "locked" in the ON position, the massive metabolic drain leads to T-cell exhaustion and epithelial damage. The VARS Triad helps mitigate this specific damage, improving recovery, reducing brain fog, and alleviating joint/muscle flares without leaving the patient vulnerable to the severe infections associated with JAK inhibitors.
- **Side Effects & Cost:** The VARS Triad has a highly favorable safety profile with minimal side effects when taken correctly. It is vastly more affordable than pharmaceutical biologics, making it a sustainable, long-term cornerstone for chronic inflammatory management.

Diagrams

Diagram 1 – Disease Overview & Attack on Key Body Parts



Diagram 2 – How Oxidative Stress Drives Pathological CCL5 Elevation



Diagram 3 – Treatment Options + VARS Triad Mechanism



References

Abadie, V., & Jabri, B. (2014). IL-15: a central regulator of celiac disease immunopathology. *Immunological Reviews*, *260*(1), 221-234. https://doi.org/10.1111/imr.12191

Cited by: 327

Lähdeaho, M.-L., Scheinin, M., Vuotikka, P., et al. (2019). Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. *The Lancet Gastroenterology & Hepatology*, *4*(12), 948-959. https://doi.org/10.1016/s2468-1253(19)30264-x

Cited by: 148

Li, Z., Wrangle, J., He, K., et al. (2025). IL-15: from discovery to FDA approval. *Journal of Hematology & Oncology*, *18*(1). https://doi.org/10.1186/s13045-025-01664-8

Cited by: 32

Machado Diaz, A. C., Chico Capote, A., Arrieta Aguero, C. A., et al. (2012). Proinflammatory Soluble Interleukin-15 Receptor Alpha Is Increased in Rheumatoid Arthritis. *Arthritis*, *2012*, 1-7. https://doi.org/10.1155/2012/943156

Cited by: 24

Mishra, A., Liu, S., Sams, G. H., et al. (2012). Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. *Cancer Cell*, *22*(5), 645-655. https://doi.org/10.1016/j.ccr.2012.09.009

Cited by: 231

Scarmozzino, F., Pizzi, M., Pelizzaro, F., et al. (2023). Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges. *Frontiers in Oncology*, *13*. https://doi.org/10.3389/fonc.2023.1273305

Cited by: 27

10 Word Description for the MaxGen Comprehensive Cytokine DRP Panel

Cytokine driving autoimmune destruction of intestinal epithelium and synovial joints.